Allyl isothiocyanate ameliorates metabolic dysfunction-associated steatotic liver disease <i>via</i> vitamin D receptors in hepatocytes

AITC provides a robust molecular basis for improving MASLD by activating hepatic VDR and driving the downstream HNF-4α/MTTP/ApoB signaling pathway. This pathway reduces hepatic lipid accumulation, promotes FA β-oxidation, and improves insulin resistance, establishing AITC as a promising treatment for MASLD.